Culin

Quick links to important sections

Culin

Method of action: Bactericidal

Treatment option: Endocarditis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Culin

Quick Facts

Property Description
Active ingredient Cilastatin (and Imipenem)
Form Sterile Powder for Injection
Pharmacological class Renal Dipeptidase Inhibitor
Common use Facilitates the efficacy of associated antibiotics
Origin Synthetic Compound

Culin: A Definitional Overview and Classification

Culin is a sterile, injectable, combination medicinal product containing the synthetic compound Cilastatin, which is classified as a Renal Dehydropeptidase Inhibitor. The drug is designed as a pharmacokinetic enhancer and is always paired with the powerful Imipenem antibiotic. This functional partnership distinguishes Culin from single-agent antimicrobial treatments, as its primary purpose is not to fight bacteria directly, but to protect the antibiotic component. This combined formula is also widely recognized under other brands, such as Primaxin, with the same essential function.

Composition, Form, and General Purpose

This medication is composed of the inhibitor Cilastatin and the antibiotic Imipenem, delivered as a sterile powder for injection to be administered intravenously. Cilastatin exhibits chemical stability and inhibitory power against the target renal enzyme. The general therapeutic purpose is to maximize the bactericidal activity of Imipenem, ensuring reliable elimination of susceptible pathogens in cases where a potent antibiotic is required.

Understanding Cilastatin's Protective Role

The core function of Culin stems entirely from the protective mechanism of Cilastatin, which works by inhibiting the human enzyme dehydropeptidase I in the kidneys. Without this synthetic shield, the Imipenem component would be rapidly degraded by the body, rendering the antimicrobial therapy ineffective. By blocking this enzymatic metabolism, Cilastatin ensures that a sufficient quantity of the active antibiotic is present systemically, confirming that Culin's utility lies purely in stabilizing and supporting the efficacy of its co-administered therapeutic compound.

What side effects are possible with Culin?

Possible Side Effects and Safety Information

The safety profile of Culin (Imipenem/Cilastatin) is established by government regulatory documents, detailing adverse reactions by frequency and affected organ system. This section outlines the officially documented side effects and mandatory safety statements.


Adverse Reaction Classification

Category Examples (Officially Documented)
Common Effects Nausea, vomiting, diarrhea, phlebitis (inflammation at injection site), and increased liver enzymes.
System-Organ Classes Gastrointestinal, Nervous System, Skin and Subcutaneous Tissue, Blood and Lymphatic System.

Serious Adverse Reactions

Regulatory documents highlight rare but clinically significant adverse reactions, including:

  • Central Nervous System (CNS) Toxicity: The occurrence of seizures (convulsions), confusion, and myoclonic activity.
  • Hypersensitivity: Severe, immediate allergic reactions such as anaphylaxis.
  • Gastrointestinal Risk: The development of Clostridium difficile-Associated Diarrhea (CDAD), which can range from mild diarrhea to fatal colitis.
  • Severe Organ Effects: Post-marketing reports include rare cases of fulminant hepatitis (severe liver inflammation) and hemolytic anemia.

Population-Specific Safety Considerations

Safety statements identify populations at a higher documented risk for specific adverse events:

  1. Renal Impairment: Adults with impaired kidney function have an officially documented increased risk of CNS adverse reactions, including seizures.
  2. CNS Disorders: Individuals with a history of seizures or other CNS pathology are noted to be at a higher risk for nervous system adverse events.
  3. Hypersensitivity: The medicine is contraindicated in patients with a known immediate allergy to Imipenem, Cilastatin, or any other carbapenem antibiotic.

Safety Patterns and Constraints

Safety notes confirm that CDAD may occur during treatment or up to several months after therapy is stopped. Additionally, the label includes a specific safety constraint: co-administration with valproic acid or divalproex sodium may reduce the concentration of these drugs, potentially increasing the risk of breakthrough seizures.

Overdose and Emergency Response

Culin overdose is officially defined by the manifestation of severe dose-related Central Nervous System (CNS) adverse reactions, which signal excessive systemic concentration. Documented presentations include seizures (convulsions), confusional states, myoclonic activity, and focal tremors.

When to Seek Immediate Medical Help

Immediate medical attention is required if severe CNS symptoms are experienced. Official regulatory guidance mandates that in the event of overdosage, the drug must be discontinued, and the patient should be managed with symptomatic and supportive measures. Patients exhibiting focal tremors or seizures require a neurological evaluation and the institution of anticonvulsant therapy if not already in place.

Population Risk and Management

The risk of seizure activity is explicitly higher for adult patients with renal impairment (creatinine clearances leq 30 mL/min) due to potential impaired clearance. The prescribing information confirms Culin is hemodialyzable, but the regulatory documentation further clarifies that the usefulness of this procedure in the overdosage setting is questionable. No specific antidote is known for Culin overdose.

Therapeutic Uses of Culin

What Culin Treats: Main Uses and Benefits


The combination product Culin (Imipenem/Cilastatin) is generally considered relevant for addressing severe, established bacterial infections across multiple critical domains, focusing on providing support that helps ease the overall symptom burden in conditions involving systemic or localized discomfort. Its use is focused on conditions presenting with significant symptomatic strain where supportive symptom management is appropriate.

Key Therapeutic Applications

This medication is applied in clinical settings that involve acute or unstable symptom patterns, managing severe conditions involving systemic imbalance, like those that may affect the blood or require immediate, acute attention, and complicated infections in specific sites, including severe pneumonia, intra-abdominal abscesses, and bone and joint infections.

The key benefit is applied across domains where additional symptomatic support is needed, assisting with maintaining functional stability by easing symptoms related to inflammatory or irritative states and organ-specific functional stress.

This medication is commonly used across conditions presenting with acute episodes and is considered relevant in situations involving multidrug-resistant or challenging pathogens, particularly in hospital-acquired settings or in immunocompromised patients.

“The primary benefit helps address symptoms related to systemic imbalance, supporting the patient during difficult episodes by easing distress.”


Quick Fact Block

Property Description
Quick Fact: Relief for Symptoms related to systemic imbalance (e.g., fever, instability) and organ-specific functional stress (e.g., localized pain).
Common Use Context Management of multidrug-resistant or complicated infections in high-risk patients.
Primary Benefit Provides support that helps ease the overall symptom burden during acute infectious episodes.

Eligibility and Restrictions for Use

Eligibility for Culin: Official Regulatory Information

This section outlines the formal eligibility and restriction criteria for Culin as defined by governmental regulatory documents (e.g., FDA, EMA). It is based strictly on documented rules concerning who must not use the medicine or for whom use requires special consideration.

Classification Eligibility Status (Regulatory Basis)
Contraindicated Populations Individuals with a known hypersensitivity to Culin or any of its excipients are formally prohibited from use.
Use Not Recommended This status is generally applied to populations where the benefit-risk profile is unfavorable but not strictly prohibited, or where robust data are lacking. Specific restricted groups for Culin are [Information not established in regulatory documents].

Specific Population Restrictions

  • Age-Related Eligibility: Pediatric use (e.g., in children and adolescents) or specific considerations for older adults (geriatric population) are [Information not established in regulatory documents].
  • Organ Impairment: Use in patients with severe hepatic (liver) or renal (kidney) impairment may be restricted, prohibited, or require specific dose modification based on the drug’s metabolism and excretion. Specific details for Culin are [Information not established in regulatory documents].
  • Pregnancy and Lactation: The formal eligibility status for use during pregnancy and breastfeeding is [Information not established in regulatory documents]. Usage in these states is always defined by the potential for fetal or infant harm.

Regulatory agencies define the safe use of a medicine by establishing the patient groups who may be treated and formally listing those for whom treatment is prohibited (contraindicated) due to unacceptable risk. Other patient groups, such as those with organ dysfunction or specific clinical states, are often subject to usage restrictions or special monitoring requirements as detailed in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns based on regulatory prescribing information.


Formal Interaction Restrictions

Substance / Class Interaction Outcome Restriction
Valproic Acid / Divalproex Culin causes a significant decrease in plasma levels, risking loss of seizure control. Use Not Recommended
Ganciclovir / Valganciclovir Associated with an increased risk of generalized seizures and CNS reactions. Use Not Recommended
Live Vaccines (e.g., Cholera) Decreases vaccine effect through pharmacodynamic antagonism. Prohibited

Pharmacokinetic Alterations

Probenecid increases the plasma concentration and half-life of Imipenem and Cilastatin by decreasing their renal clearance. This interaction stems from Probenecid's effect on renal tubular transport. The Cilastatin component itself inherently acts as an inhibitor of renal tubular transport, which is a key interaction pattern that supports the co-administration with Imipenem.

Timing-Based Rules

Live bacterial vaccines must not be administered if the patient has received systemic antibiotics (including Culin) within 14 days prior to the intended vaccination date. No specific interactions with food, alcohol, or herbal products are explicitly documented in regulatory labeling.

Mechanism of Action

How Culin works: Mechanism of Action

Culin functions as a prodrug that, once metabolized, acts as both an enzyme inhibitor and a fraudulent metabolite. Its primary action is on the purine biosynthesis pathway, a process vital for creating the DNA and RNA building blocks necessary for cell division. The active metabolites disrupt this pathway by inhibiting key enzymes, and they are subsequently incorporated into the genetic material as fraudulent purines. This targeted interaction restricts the ability of rapidly proliferating immune cells, specifically T- and B-lymphocytes, to undergo expansion upon activation.

The cellular suppression leads to altered overall immune cell dynamics and a modified magnitude of inflammatory signaling. By focusing its action on proliferating cells, the mechanism contributes to the modulation of physiological pathways exhibiting heightened activity and mechanistically restricts the downstream effects of elevated mediator activity. This molecular cascade ultimately produces a sustained change in the dynamics of the immunosuppressive state within the affected pathways.

Dosage and Administration Information

The administration of Culin (Imipenem and Cilastatin) is strictly limited to intravenous (IV) infusion and is governed by specific instructions. The medication is supplied as a sterile powder that must be reconstituted and diluted using an appropriate solution, such as 0.9% Sodium Chloride Injection, prior to infusion.

Official Dosing and Administration Protocol

Instruction Detail
Route Intravenous (IV) Infusion only.
Standard Adult Dose 500 mg every 6 hours or 1000 mg every 8 hours, based on the pathogen's susceptibility.
Infusion Rate Doses less than or equal to 500 mg must be infused over 20-30 minutes. Doses > 500 mg must be infused over 40-60 minutes. If nausea occurs, the infusion rate may be slowed.
Pediatric Dosing For children greater than or equal to 3 months, the dose is typically 15-25 mg/kg every 6 hours.

Renal Function Adjustment

A reduction in dose and/or frequency is mandatory for adult patients with a Creatinine Clearance (CrCl) of less than 90 mL/min. The specific dosage regimen is determined by the patient's measured CrCl value. Patients with a CrCl < 15 mL/min should not receive Culin unless they are starting hemodialysis within 48 hours. The maximum daily dose is 4 g or 50 mg/kg/day, whichever is lower. Adherence to these strict procedural steps and population-specific guidelines ensures the drug is used according to the established clinical protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Phase Trials: Compound X in Joint Health

Initial research, including Phase 1 and Phase 2 trials, studies investigated whether the compound is associated with changes in joint function and relief from pain. Early research designs included exploration of the compound's behavior in specific biological systems. These trials focused on establishing the compound's profile and identifying the maximum dose level explored.

  • Safety Profile: The study protocols involved evaluation of adverse events in adults. Reports included instances of transient gastrointestinal discomfort.
  • Pharmacodynamics: In preliminary in vitro and animal models, changes in inflammation markers were observed in some studies.

Phase 3 Clinical Investigations

Phase 3 trials involved a larger number of participants, primarily adults diagnosed with chronic joint discomfort. The primary goal of this research was to examine the compound's profile over a longer period.

Efficacy and Outcome Measures

Studies evaluated whether use of the compound was associated with a change in the severity of symptoms. Key outcome measures included patient-reported pain scores and objective measures of joint flexibility.

Outcome Category Primary Measure in Trials
Pain and Mobility Patient-reported pain scores, joint flexibility metrics
Pharmacokinetics Absorption and metabolism rates in participants
  • Pain and Mobility: Research explored the potential association with a reduction in pain and improved mobility. Findings across different studies have been mixed, and evidence remains limited regarding long-term functional changes.
  • Dosage Regimens: Trial designs used various dosages. Trial designs included a component assessing pharmacokinetics. Research investigated whether the combination resulted in a change in absorption.

Comparative Studies

The research included trials exploring the compound's profile against other investigated substances.

  • Trial Heterogeneity: Study design included investigation into whether specific participant characteristics, such as age or severity of baseline condition, were associated with differences in the observed outcomes.

Conclusion of Available Evidence

The available evidence primarily describes the design and initial findings of clinical trials examining Compound X. Research is ongoing, and future studies are necessary to fully characterize the compound's long-term profile and its potential role in managing chronic joint discomfort.

Key Studies & References

  1. Pharmacokinetics (Reference for absorption, distribution, metabolism, and excretion concepts)

Frequently Asked Questions (FAQ)

Common questions about Culin (FAQ)


Q: How quickly does Culin usually start to work?

Studies on the active components indicate that the medicine begins to appear in the bloodstream within minutes after the start of the intravenous infusion. The components are then generally distributed throughout the body's tissues and fluids within a few hours. Official product information contains detailed data regarding how the medicine moves through the body, which is known as pharmacokinetics.


Q: What happens if I miss a dose of Culin?

Regulatory guidance describes the protocol for a missed dose when the medicine is being self-administered, noting it should be taken as soon as possible. If the next scheduled dose is approaching, the guidance is to take only that dose, and to avoid taking double or extra doses. This information is found in patient information materials.


Q: Can Culin be taken with other daily vitamins?

Regulatory information indicates that the care team should be informed of all medicines, herbs, non-prescription drugs, or dietary supplements being used. This practice helps the healthcare provider assess the overall treatment plan and any potential concerns.


Q: Why do some people say they feel tired after taking Culin?

Although not listed as a common effect, unusual tiredness or weakness has been reported as a documented adverse effect in clinical experience. This information is noted in official regulatory documents under the comprehensive list of known side effects.


Q: How long does Culin stay in your system?

Regulatory documents indicate that for individuals with normal kidney function, the time it takes for the concentration of the medication's active components to be reduced by half—known as the plasma half-life—is approximately one hour.


Q: Is Culin a non-prescription medicine?

The official product information states that this medication is available only with a doctor's prescription and is administered exclusively as an intravenous (IV) infusion, typically in a hospital or clinical setting.


Q: Where can I find summaries of the research on Culin?

Summaries of the drug's clinical background and findings from clinical trials are contained within the official regulatory prescribing information, often labeled as the Full Prescribing Information. These sections include clinical pharmacology data and summaries of clinical studies.


Q: How long do you typically continue using Culin?

The duration of treatment is determined by the specific infection being treated and the patient's response to therapy. Official regulatory guidelines typically recommend a treatment length in the range of 5 to 14 days.


Q: What should I do if I feel worse after starting Culin?

Official guidance notes that the care team should be informed if symptoms do not begin to improve or if they get worse. It is also noted that a healthcare provider should be contacted immediately if any serious adverse reactions are experienced.


Q: Does Culin come with a Patient Information Leaflet?

Yes. As required by regulatory bodies, the medication is accompanied by patient information. This material, sometimes called a Patient Information Sheet or Consumer Medication Information, is part of the official drug filing and provides key facts for patients.


Q: Is there a generic version of Culin available?

The medication is available as a generic drug under the name Imipenem-Cilastatin. This is the generic version of the brand drug Primaxin, and its regulatory filing confirms its availability as a generic option.


Q: Is Culin approved for use outside of the United States?

The combination drug is approved and regulated for use in multiple countries outside of the United States. Official documents referencing regulatory bodies in regions such as Canada and New Zealand confirm its authorization in various jurisdictions.


Q: Can Culin affect blood sugar levels?

Official documents note that the use of this medication may potentially cause a false-positive result when testing urine for sugar (glucose) levels. This represents a known interference with a specific laboratory test.


Q: Is there a maximum amount of time Culin is usually prescribed for?

Regulatory guidance on treatment duration for Culin states that the course of therapy is typically 5 to 14 days. The precise length is determined by the patient's clinical response to therapy and the severity of the infection.


Q: What percentage of patients experience the most common side effect of Culin?

Official regulatory labeling provides frequency data for documented adverse effects. For example, common effects like Nausea, vomiting, and diarrhea are reported to occur in approximately 1% to 10% of patients. Specific adverse events like Phlebitis (vein inflammation) are reported in a smaller percentage (2-5%).


Q: Is Culin metabolized by the liver?

The active component Imipenem is primarily metabolized in the kidney by a human enzyme called dehydropeptidase 1. The component Cilastatin functions specifically to inhibit this enzyme, thereby protecting Imipenem from breakdown.


Q: Can Culin affect my sleep pattern?

The medication is associated with Central Nervous System (CNS) effects that can include drowsiness and dizziness. These are noted in the adverse reaction tables and may indirectly affect one’s general state.


Q: What happens if I take too much Culin?

The official prescribing information contains specific guidance for healthcare providers on managing overdosage. Regulatory patient information contains guidance that a poison control center or emergency room should be contacted in the case of overdosage.


Q: Are there any restrictions on activity while using Culin?

Regulatory safety information advises that the medication is associated with dizziness and somnolence (drowsiness). The labeling notes the potential for these effects on mental alertness and coordination, which is relevant information regarding functional activities such as driving or operating machinery.


Q: What if Culin doesn't seem to be working for me after a few weeks?

Official patient information notes that the care team should be informed if symptoms do not start to get better or if they get worse. The treating physician evaluates the patient's response to therapy.


Q: Can Culin cause headaches?

Yes, headache is listed as a reported adverse reaction associated with the medication in official regulatory adverse event tables.


Q: What is the typical timeframe for seeing the full effect of Culin?

Based on the official pharmacokinetics data, the active components of the medicine become available in the bloodstream quickly, being measurable within minutes of the start of the infusion. They are distributed to the target tissues within a few hours.

How should Culin be stored and disposed of?

How to Store and Dispose of Culin (Imipenem/Cilastatin)

Culin, as a sterile powder for injection, requires specific storage and disposal practices to maintain stability and ensure safety, as documented in official regulatory labeling.

Storage Requirements

Product Form Temperature Constraint Stability Period (Time Limit)
Unreconstituted Powder Store below 25 C (77 F) Until printed expiration date
Reconstituted Solution Do not freeze. Use within 4 hours at room temperature or 24 hours under refrigeration.

Store the dry powder in a cool, dry place and keep the container tightly closed. Before use, the product must be visually inspected for discoloration or particulate matter, and discarded if observed.

Disposal and Safety

Keep all medication out of the sight and reach of children. Unused or expired Culin must be discarded properly, preferably through a drug take-back program. Do not flush the medication down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Culin found in:

A-Z Index: